Resolian, a global bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, has acquired Denali Medpharma, a leading China-based bioanalytical CRO. Resolian now has bioanalysis laboratory operations in the U.S., U.K., Australia, and China. The company can initiate a project on four continents and easily transfer validated methods across labs, allowing therapeutic trials to extend to virtually any destination without changing bioanalytical CROs.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!